+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Hereditary Genetic Testing Market Competition Forecast and Opportunities, 2028

  • PDF Icon

    Report

  • 76 Pages
  • August 2023
  • Region: United States
  • TechSci Research
  • ID: 5869890
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

United States Hereditary Genetic Testing Market is anticipated to witness a steady CAGR in the forecast period, 2024-2028. This can be ascribed to the growing frequency of hereditary disorders in the US. Similarly, growing advancements in genetic analysis and the advent of rare diseases are expected to drive the growth of the market during the forecast period. Additionally, growing concern about women’s health will enhance the demand for the US hereditary genetic testing market over the years. Also, the growing existence of significant businesses offering genetic tests, the widespread use of modern therapies, and government guidelines to maintain the integrity of hereditary genetic testing screening are expected to drive the growth of the market in the forecast period.

Rising Prevalence of Chronic Disorders

Growing incidence of genetic disorders and cancer rapidly across the US will further increase the demand for US hereditary genetic testing market during the forecast period. One of the major factors is early and preventive care which is expected to drive the growth of the market in the forecast period. Also, the growing economic burden for the treatment of diseases is leading to a stronger focus of healthcare providers and government bodies towards the early diagnosis and screening for health risks. According to the American Cancer Society, almost 1.8 million new patients with cancer were diagnosed in 2020. Around 606,520 cancer deaths were reported in the United States in 2020, making cancer the second-highest death-causing disease worldwide. Various types of cancers are inherited from generation to generation due to gene mutations. So, genetic testing is widely used for studying the pattern and prevention of gene mutation, treatment of diseases, and drug discovery. Similarly, cytogenetics helps to study chromosomes to provide a better knowledge of cancers such as breast cancer.

Growing Demand for Personalized Medicine

Growing demand for personalized medicine for treating individual patients’ diseases will further drive the growth of the market over the years. So, large-scale drug discovery is necessary for increasing the feasibility and practicality of personalized medicines for the detection of genetic disorders as well as diseases. Genetic testing is used in pharmacogenomics for drug-gene testing, and it can help to accelerate drug development. So, researchers are more aware of the treatments of customized diseases by using genetic testing techniques such as cytogenetic testing (fluorescence in situ hybridization, microarray, and others), biochemical testing, molecular testing, and DNA sequencing. Moreover, the growing demand for primary patient care by physicians using genetic testing is expected to rise the demand for the hereditary genetic testing market over the years. In addition, consumer awareness of personalized medicines increased to 33% in 2019 from 29% in 2018.

Growing Advancement in Genetic Testing

Growing advancements in genetic testing such as the use of chromosomal microarray analysis and biochip for the detection of genetic disorders including NGS transforms the method of determination of structural and numerical abnormalities in chromosomes and this in turn leads to the detection of various type of rare genetic disorders and drives the growth of the market over the years. Technological advancements also contribute towards developing the non-invasive cell-free fatal DNA for identifying sub chromosomal abnormalities, single gene disorders and chromosomal aneuploidy, which will further propel the growth of the market. Further, these technologies contribute towards the development of carrier screens that allow the simultaneous detection of different genetic disorders. In September 2019, Roche launched a blood-based genomic profiling test, FoundationOne Liquid and this test can detect 70 most common mutated genes in solid tumors and microsatellite instability. These types of development in genetic testing products by major key players are expected to drive the growth for the hereditary genetic testing market during the forecast period.

Market Segmentation

United States Hereditary Genetic Testing market can be segmented by technique, application, payer, end user, region and competitive landscape.. Based on technique, the market can be segmented into PCR, DNA Sequencing, Microarrays, Others. Based on application, the market can be differentiated into Cardiology, Oncology, Pharmacogenomics, Cognitive Dysfunction, Pathogenomics, Others. Based on payer, the market can be differentiated into Public Health Insurance, Private Health Insurance, Out of Pocket. Based on end user, the market can be divided into Hospitals, Independent Laboratories.

Recent Development

  • For instance, in July 2020, Myriad Genetics, Inc. launched proprietary AMPLIFY technology, which increases performance of its Prequel noninvasive prenatal screening (NIPS) test.

  • In addition, Myriad also launched New GeneSight psychotropic patient collection kit in June 2020. This kit allows DNA sample collection, typically administered in a clinician’s office, to be completed at home.

Market Players

Invitae Corporation, Ambry Genetics, BioReference Laboratories Inc, Progenity Inc., Pathema Gx Lab, LLC., Quest Diagnostics Incorporated, Myriad Genetics Inc., Fulgent Genetics, Inc., Burning Rock Biotech Limited are some of the leading players operating in the United States Hereditary Genetic Testing market.

Report Scope:

In this report, United States Hereditary Genetic Testing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

United States Hereditary Genetic Testing Market, By Technique:

  • PCR
  • DNA Sequencing
  • Microarrays
  • Others

United States Hereditary Genetic Testing Market, By Application:

  • Cardiology
  • Oncology
  • Pharmacogenomics
  • Cognitive Dysfunction
  • Pathogenomics
  • Others

United States Hereditary Genetic Testing Market, By Payer:

  • Public Health Insurance
  • Private Health Insurance
  • Out of Pocket

United States Hereditary Genetic Testing Market, By End User:

  • Hospitals
  • Independent Laboratories

United States Hereditary Genetic Testing Market, By Region:

  • Northeast
  • Mid-west
  • West
  • South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Hereditary Genetic Testing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States Hereditary Genetic Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technique (PCR, DNA Sequencing, Microarrays, Others)
5.2.2. By Application (Cardiology, Oncology, Pharmacogenomics, Cognitive Dysfunction, Pathogenomics, Others)
5.2.3. By Payer (Public Health Insurance, Private Health Insurance, Out of Pocket)
5.2.4. By End User (Hospitals, Independent Laboratories)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
5.3.1. By Technique
5.3.2. By Application
5.3.3. By Payer
5.3.4. By End User
5.3.5. By Region
6. North-East United States Hereditary Genetic Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technique
6.2.2. By Application
6.2.3. By Payer
6.2.4. By End User
7. Mid-West United States Hereditary Genetic Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technique
7.2.2. By Application
7.2.3. By Payer
7.2.4. By End User
8. West United States Hereditary Genetic Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technique
8.2.2. By Application
8.2.3. By Payer
8.2.4. By End User
9. South United States Hereditary Genetic Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technique
9.2.2. By Application
9.2.3. By Payer
9.2.4. By End User
10. Market Dynamics
10.1. Drivers
8.1.1 Growing Prevalence of Chronic Disorders
8.1.2 Growing Demand for Personalized Medicine
8.1.3 Growing Advancement in Genetic Testing
10.2. Challenges
8.2.1 Clinical issues of DNA test kits
8.2.2 Regulatory challenges pertaining to the use of DTC genetic tests
11. Market Trends & Developments12. Policy & Regulatory Landscape13. United States Economic Profile14. United States Hereditary Genetic Testing: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.5.1. Invitae Corporation
16.5.2. Ambry Genetics
16.5.3. BioReference Laboratories Inc.
16.5.4. Progenity Inc.
16.5.5. Pathema Gx Lab, LLC
16.5.6. Quest Diagnostics Incorporated
16.5.7. Myriad Genetics Inc.
16.5.8. Fulgent Genetics, Inc.
16.5.9. Burning Rock Biotech Limited.
17. Strategic Recommendations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Invitae Corporation
  • Ambry Genetics
  • BioReference Laboratories Inc.
  • Progenity Inc.
  • Pathema Gx Lab, LLC
  • Quest Diagnostics Incorporated
  • Myriad Genetics Inc.
  • Fulgent Genetics, Inc.
  • Burning Rock Biotech Limited

Table Information